Literature DB >> 21217769

Fluoxetine inhibited extracellular matrix of pulmonary artery and inflammation of lungs in monocrotaline-treated rats.

Xue-qin Li1, Han-ming Wang, Chun-guang Yang, Xin-hua Zhang, Dan-dan Han, Huai-liang Wang.   

Abstract

AIM: To investigate the effects of the selective serotonin reuptake inhibitor (SSRI) fluoxetine on extracellular matrix (ECM) remodeling of the pulmonary artery and inflammation of the lungs in pulmonary arterial hypertension (PAH) induced by monocrotaline in rats.
METHODS: MCT-induced chronic PAH was established in Wistar rats. After treatment with fluoxetine for 3 weeks, pulmonary hemodynamic measurement and morphological investigation of lung tissues were undertaken. The main components of the ECM, elastin and collagen, were detected using Van Gieson stain and Orcein stain, respectively, or using Victoria-ponceau's double stain. The ECM proteolytic enzymes matrix metalloproteinase (MMP)-2 and MMP-9, and the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2, were detected by Western blot. Inflammation of lung tissue was assayed using lung morphology and inflammatory cytokine expression.
RESULTS: Fluoxetine (2 and 10 mg/kg) significantly inhibited MCT-induced PAH, attenuated pulmonary arterial muscularization and ECM remodeling, and decreased MMP/TIMP expression. Fluoxetine also suppressed inflammatory responses in lung tissue and inhibited the expression of the inflammatory cytokines interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), monocyte chemotactic protein (MCP-1) and intercellular adhesion molecule-1 (ICAM-1).
CONCLUSION: Fluoxetine inhibited MCT-induced ECM remodeling of the pulmonary artery and inflammation of lung tissue. These effects were related to its inhibition on MMPs/TIMPs and cytokine productions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21217769      PMCID: PMC4085716          DOI: 10.1038/aps.2010.187

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  37 in total

Review 1.  Possible role of matrix metalloproteinases in reconstruction of peripheral pulmonary arteries induced by hypoxia.

Authors:  J Novotná; J Herget
Journal:  Physiol Res       Date:  2002       Impact factor: 1.881

2.  Gelatinase expression in pulmonary arteries during experimental pulmonary hypertension.

Authors:  E Frisdal; V Gest; A Vieillard-Baron; M Levame; H Lepetit; S Eddahibi; C Lafuma; A Harf; S Adnot; M P Dortho
Journal:  Eur Respir J       Date:  2001-11       Impact factor: 16.671

Review 3.  Matrix metalloproteinases. A review.

Authors:  H Emonard; J A Grimaud
Journal:  Cell Mol Biol       Date:  1990       Impact factor: 1.770

Review 4.  The serotonin receptor and transporter as potential therapeutic targets for pulmonary hypertension.

Authors:  Huai-Liang Wang
Journal:  Curr Opin Investig Drugs       Date:  2004-09

5.  Serotonin activates murine alveolar macrophages through 5-HT2C receptors.

Authors:  Zbigniew Mikulski; Zbigniew Zaslona; Lidija Cakarova; Petra Hartmann; Jochen Wilhelm; Laurence H Tecott; Juergen Lohmeyer; Wolfgang Kummer
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-05-21       Impact factor: 5.464

6.  High plasma serotonin levels in primary pulmonary hypertension. Effect of long-term epoprostenol (prostacyclin) therapy.

Authors:  A Kéreveur; J Callebert; M Humbert; P Hervé; G Simonneau; J M Launay; L Drouet
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-10       Impact factor: 8.311

7.  Serotonin regulation of gene expression in uterine extracellular matrix: reciprocal effects on collagens and collagenase.

Authors:  T V Passaretti; B D Wilcox; J J Jeffrey
Journal:  Mol Cell Endocrinol       Date:  1996-07-01       Impact factor: 4.102

8.  Serotonin-induced MMP-13 production is mediated via phospholipase C, protein kinase C, and ERK1/2 in rat uterine smooth muscle cells.

Authors:  Jenny K S Shum; J Andres Melendez; John J Jeffrey
Journal:  J Biol Chem       Date:  2002-09-03       Impact factor: 5.157

Review 9.  Inflammation in pulmonary arterial hypertension.

Authors:  P Dorfmüller; F Perros; K Balabanian; M Humbert
Journal:  Eur Respir J       Date:  2003-08       Impact factor: 16.671

10.  Studies on the anti-inflammatory effect of fluoxetine in the rat.

Authors:  Omar M E Abdel-Salam; Ayman R Baiuomy; Mahmoud S Arbid
Journal:  Pharmacol Res       Date:  2004-02       Impact factor: 7.658

View more
  13 in total

1.  Fluoxetine inhibits inflammatory response and bone loss in a rat model of ligature-induced periodontitis.

Authors:  Luciana S Branco-de-Almeida; Gilson C Franco; Myrella L Castro; Juliana G Dos Santos; Ana Lia Anbinder; Sheila C Cortelli; Mikihito Kajiya; Toshihisa Kawai; Pedro L Rosalen
Journal:  J Periodontol       Date:  2011-10-03       Impact factor: 6.993

2.  Rho-kinase inhibitor Y-27632 attenuates pulmonary hypertension in hyperoxia-exposed newborn rats.

Authors:  Hsiu-Chu Chou; Liang-Ti Huang; Tsu-Fu Yeh; Chung-Ming Chen
Journal:  Acta Pharmacol Sin       Date:  2013-08-26       Impact factor: 6.150

3.  Immune-Regulatory and Molecular Effects of Antidepressants on the Inflamed Human Keratinocyte HaCaT Cell Line.

Authors:  Curzytek K; Maes M; Kubera M
Journal:  Neurotox Res       Date:  2021-05-04       Impact factor: 3.911

4.  The expression of HoxB5 and SPC in neonatal rat lung after exposure to fluoxetine.

Authors:  Razieh Taghizadeh; Zahra Taghipour; Akbar Karimi; Ali Shamsizadeh; Mohammad Mohsen Taghavi; Mahdi Shariati; Ahmad Shabanizadeh; Hamid Reza Jafari Naveh; Reza Bidaki; Fariba Aminzadeh
Journal:  Drug Des Devel Ther       Date:  2016-11-02       Impact factor: 4.162

5.  TNFα drives pulmonary arterial hypertension by suppressing the BMP type-II receptor and altering NOTCH signalling.

Authors:  Liam A Hurst; Benjamin J Dunmore; Lu Long; Alexi Crosby; Rafia Al-Lamki; John Deighton; Mark Southwood; Xudong Yang; Marko Z Nikolic; Blanca Herrera; Gareth J Inman; John R Bradley; Amer A Rana; Paul D Upton; Nicholas W Morrell
Journal:  Nat Commun       Date:  2017-01-13       Impact factor: 14.919

6.  Heme oxygenase-1 and inflammation in experimental right ventricular failure on prolonged overcirculation-induced pulmonary hypertension.

Authors:  Asmae Belhaj; Laurence Dewachter; François Kerbaul; Serge Brimioulle; Céline Dewachter; Robert Naeije; Benoît Rondelet
Journal:  PLoS One       Date:  2013-07-25       Impact factor: 3.240

7.  A modified Verhoeff's elastin histochemical stain to enable pulmonary arterial hypertension model characterization.

Authors:  K R Percival; Z A Radi
Journal:  Eur J Histochem       Date:  2016-02-11       Impact factor: 3.188

8.  Activation of AMPK Prevents Monocrotaline-Induced Extracellular Matrix Remodeling of Pulmonary Artery.

Authors:  Shaojun Li; Dong Han; Yonghong Zhang; Xinming Xie; Rui Ke; Yanting Zhu; Lu Liu; Yang Song; Lan Yang; Manxiang Li
Journal:  Med Sci Monit Basic Res       Date:  2016-03-09

9.  The protective effects of PCPA against monocrotaline-induced pulmonary arterial hypertension are mediated through the downregulation of NFAT-1 and NF-κB.

Authors:  Yang Bai; Zhong-Xia Li; Huai-Liang Wang; Guo-Chao Lian; Yun Wang
Journal:  Int J Mol Med       Date:  2017-05-26       Impact factor: 4.101

10.  Matrix metalloproteinases are possible targets in monocrotaline-induced pulmonary hypertension: investigation of anti-remodeling effects of alagebrium and everolimus.

Authors:  Özlem Atlı; Sinem Ilgın; Bülent Ergun; Dilek Burukoğlu; Ahmet Musmul; Başar Sırmagül
Journal:  Anatol J Cardiol       Date:  2016-04-26       Impact factor: 1.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.